menu
    • menu

    Company profile for Neurocrine Biosciences

    NEW Drugs in Dev: 32
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development program...
    Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson’s disease, congenital adrenal hyperplasia and uterine fibroids*.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Neurocrine BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Neurocrine Biosciences, Inc. 12780 El Camino Real San Diego, CA 92130
    Telephone
    Telephone
    1-858-617-7600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.neurocrine.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurocrine Biosciences Unveils Q1 2026 Financial Results
    Neurocrine Biosciences Unveils Q1 2026 Financial Results

    06 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-first-quarter-2026-financial-results-302763133.html

    PR NEWSWIRE
    06 May 2026
    Share Share
    Neurocrine Survey Reveals Tardive Dyskinesia's Toll on Jobs
    Neurocrine Survey Reveals Tardive Dyskinesia's Toll on Jobs

    04 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-new-survey-results-showing-significant-burden-of-tardive-dyskinesia-on-employment-302760554.html

    PR NEWSWIRE
    04 May 2026
    Share Share
    Neurocrine Starts Phase 1 Study of CRF2 Agonist NBIP-2118
    Neurocrine Starts Phase 1 Study of CRF2 Agonist NBIP-2118

    04 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbip-2118-a-corticotropin-releasing-factor-type-2-receptor-agonist-302760552.html

    PR NEWSWIRE
    04 May 2026
    Share Share
    Neurocrine Biosciences Shows Durable Hormone Control
    Neurocrine Biosciences Shows Durable Hormone Control

    01 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-durable-hormone-control-reduced-glucocorticoid-exposure-and-meaningful-clinical-improvements-in-pediatric-patients-with-classic-congenital-302759774.html

    PR NEWSWIRE
    01 May 2026
    Share Share
    Neurocrine Establishes Threshold for TD Impact Scale
    Neurocrine Establishes Threshold for TD Impact Scale

    29 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7248580

    FIRSTWORD PHARMA
    29 Apr 2026
    Share Share
    Neurocrine Buys Soleno at Discount as Europe Prospects Fade
    Neurocrine Buys Soleno at Discount as Europe Prospects Fade

    21 Apr 2026

    // ENDPOINTS NEWS

    https://endpoints.news/soleno-sold-at-a-discount-to-neurocrine-due-to-dwindling-european-prospects/

    ENDPOINTS NEWS
    21 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search